Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
NCT00238719
Last updated date
ABOUT THIS STUDY
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of
venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and
adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled
study.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Social Anxiety Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
8-17 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Male or female outpatient
- 8-17 year old
- diagnosis of Social Anxiety Disorder
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- concomitant psychiatric or medical disorders which interfere with safety or assessment
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Social Anxiety DisorderGeodon for the Treatment of Refractory Social Anxiety Disorder
NCT00215150
- Durham, North Carolina
- Durham, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Social Anxiety Disorder12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
NCT01316302
- New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Social Anxiety DisorderStudy Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
NCT00238719
ALL GENDERS
8 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder | |||
| Official Title ICMJE | A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder | |||
| Brief Summary | To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
| Condition ICMJE | Social Anxiety Disorder | |||
| Intervention ICMJE | Drug: Venlafaxine ER | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Enrollment ICMJE | 293 | |||
| Original Enrollment ICMJE | Same as current | |||
| Study Completion Date ICMJE | June 2003 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 8 Years to 17 Years (Child) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00238719 | |||
| Other Study ID Numbers ICMJE | 0600B4-389 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | May 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||